Background
coronavirus disease 2019, hematologic malignancies
CORONAVIRUS DISEASE 2019, HEMATOLOGIC MALIGNANCIES
In light of the recent coronavirus disease 2019 (COVID-19) outbreak, a serious medical crisis has been announced that is extremely harmful to patients with hematologic malignancies and those who have undergone hematopoietic stem cell transplantation (HSCT) (The approach of giving an additional COVID-19 vaccine as a homologous or heterologous prime-boost is an interesting object of research that has been addressed in several studies on healthy subjects so far (Most of the reported data on SARS-CoV-2 vaccination in HSCT patients employed mRNA-based vaccines, while a minority used an adenovirus-based vector platform (A recent publication demonstrated that the serologic response to two primary doses of RBD-TT conjugated SARS-CoV-2 vaccine (PastoCovac) shortly after autologous HSCT (auto-HSCT) was effective but not as effective as in healthy controls (